1-benzyl-3-benzyloxymethyl-2,5-diketopiperazine | 169448-85-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-benzyl-3-benzyloxymethyl-2,5-diketopiperazine
• 英文别名: 1-Benzyl-3(S)-benzyloxymethylpiperazine-2,5-dione；(3S)-1-benzyl-3-(phenylmethoxymethyl)piperazine-2,5-dione
• CAS: 169448-85-5
• 化学式: C₁₉H₂₀N₂O₃
• 分子量: 324.379
• InChiKey: FXHKCIGMMGPLKQ-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-benzyl-3-benzyloxymethyl-2,5-diketopiperazine 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (R)-N4-苄基-2-(苄氧基甲基)哌嗪
  参考文献：
  名称：

  从容易获得的α-氨基酸 有效地一锅法合成对映体纯的N保护的α-取代的哌嗪†

  摘要：

  从市售的N-保护的氨基酸开始，已开发出一条新的途径，以对映体纯的3-取代的带有苄基保护基的哌嗪，总收率良好（83-92％）。该方法代表了一种有效且简单的一锅法，采用了由Ugi-4组分反应，Boc脱保护，分子内环化反应和最终还原（UDCR）组成的合成序列。因此，还可以通过相应的哌嗪的简单保护和脱保护步骤，从苄基保护的前体中获得带有Boc保护基的2-取代的哌嗪。证明了该方法的实际实用性用于手性药物合成。

  DOI：

  10.1039/c7nj04039c
• 作为产物：
  描述：

  N-苄基甘氨酸乙酯 在 TEA 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-benzyl-3-benzyloxymethyl-2,5-diketopiperazine
  参考文献：
  名称：

  Exploring the Structure−Activity Relationships of [1-(4-tert-Butyl-3‘-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), A High-Affinity and Selective δ-Opioid Receptor Nonpeptide Agonist Ligand

  摘要：

  SL-3111 [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] is a de novo designed, high-affinity and selective nonpeptide peptidomimetic agonist of the delta-opioid receptor. In a previous report we had described the unique biological characteristics of this ligand and also a need for further structural evaluation(6). To pursue this, we have introduced a completely different heterocyclic template (2 and 3), which, based on molecular modeling studies, may present the required structural features to properly orient the pharmacophore groups. We also have made more subtle changes to the original piperazine scaffold (5 and 11). The biological activities of these compounds revealed an important participation of the scaffold in the ligand-receptor interaction. To further explore functional diversity on the scaffold, we have maintained the original piperazine ring and introduced four different functionalities at position 2 of the heterocyclic ring (15a-d; a = CH2-O-CH2-Ph; b = Me; c = CH2Ph; d = CH2OH). The biological activities observed for these compounds showed a very interesting trend in terms of the steric effects of the groups introduced at this position. A decrease of almost 2000-fold in affinity and potency at the delta-receptor was observed for 15c compared with 15b. This difference may be explained if we postulate that the bioactive conformation of these peptidomimetics is close to the minimal energy conformations calculated in our study. On the basis of these findings we have realized the importance of this position to further explore and simplify the structure of future generations of peptidomimetic ligands.

  DOI：

  10.1021/jm990337f
• 作为试剂：
  描述：

  N-BOC-O-苄基-L-丝氨酸 、 N,N'-二环己基碳二亚胺 、 二氯甲烷 、 N-苄基甘氨酸乙酯 在 1-benzyl-3-benzyloxymethyl-2,5-diketopiperazine 、 盐酸 、 二氯甲烷 、 crude product 、 乙酸乙酯 作用下， 以the title compound was obtained as a white solid (10.3 g)的产率得到1-benzyl-3-benzyloxymethyl-2,5-diketopiperazine
  参考文献：
  名称：

  Inhibitors of farnesyl-protein transferase

  摘要：

  本发明涉及抑制法尼酰蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼酰化的化合物。本发明还涉及包含本发明化合物的化疗组合物以及抑制法尼酰蛋白转移酶和致癌基因蛋白Ras的方法。式A的化合物代表本发明的化合物：##STR1##

  公开号：

  US05736539A1

文献信息

• INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
  申请人：MERCK & CO. INC.

  公开号：EP0703905A1

  公开（公告）日：1996-04-03
• PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3116862B1

  公开（公告）日：2019-04-17
• US5736539A
  申请人：——

  公开号：US5736539A

  公开（公告）日：1998-04-07
• [EN] INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE<br/>[FR] INHIBITEURS DE FARNESYLE-PROTEINE TRANSFERASE
  申请人：MERCK & CO., INC.

  公开号：WO1995000497A1

  公开（公告）日：1995-01-05

  (EN) The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.(FR) L'invention concerne des composés inhibiteurs de farnésyle-protéine transférase (Ftase) et la farnésylation de la protéine d'oncogène Ras. L'invention concerne en outre des compositions chimiothérapiques contenant les composés de l'invention, des procédés d'inhibition de farnesyle-protéine transférase et la farnésylation de la protéine d'oncogène Ras.
• Exploring the Structure−Activity Relationships of [1-(4-<i>tert</i>-Butyl-3‘-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), A High-Affinity and Selective δ-Opioid Receptor Nonpeptide Agonist Ligand
  作者：Josue Alfaro-Lopez、Toru Okayama、Keiko Hosohata、Peg Davis、Frank Porreca、Henry I. Yamamura、Victor J. Hruby

  DOI：10.1021/jm990337f

  日期：1999.12.1

  SL-3111 [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] is a de novo designed, high-affinity and selective nonpeptide peptidomimetic agonist of the delta-opioid receptor. In a previous report we had described the unique biological characteristics of this ligand and also a need for further structural evaluation(6). To pursue this, we have introduced a completely different heterocyclic template (2 and 3), which, based on molecular modeling studies, may present the required structural features to properly orient the pharmacophore groups. We also have made more subtle changes to the original piperazine scaffold (5 and 11). The biological activities of these compounds revealed an important participation of the scaffold in the ligand-receptor interaction. To further explore functional diversity on the scaffold, we have maintained the original piperazine ring and introduced four different functionalities at position 2 of the heterocyclic ring (15a-d; a = CH2-O-CH2-Ph; b = Me; c = CH2Ph; d = CH2OH). The biological activities observed for these compounds showed a very interesting trend in terms of the steric effects of the groups introduced at this position. A decrease of almost 2000-fold in affinity and potency at the delta-receptor was observed for 15c compared with 15b. This difference may be explained if we postulate that the bioactive conformation of these peptidomimetics is close to the minimal energy conformations calculated in our study. On the basis of these findings we have realized the importance of this position to further explore and simplify the structure of future generations of peptidomimetic ligands.